top of page
winter webinar background wix.png

Longwood Healthcare Leaders
Stanford/San Francisco CEO

January 6 - 7, 2024

Longwood Healthcare Leaders Stanford/San Francisco CEO brings together leading biopharma CEOs, heads of R&D, top academic researchers, and life science investors the weekend prior to the JP Morgan Healthcare Conference for off-the-record discussion, co-hosted by Stanford Med Dean Lloyd Minor and former Stanford President Marc Tessier-Lavigne, held at the Four Seasons San Francisco.

Join us for an intimate event with leaders in the industry.

Featured Speakers

Featured Speakers

Agenda

Day 1

Saturday, January 6, 2024

7:00 am

REGISTRATION & NETWORKING BREAKFAST

 

7:30 am

LONGWOOD FUND INTRODUCTION

 

8:00 am

BIG BIOPHARMA PIPELINE SOURCING

Shiva Malek, Global Head, Oncology, Novartis

Frank Nestle, Global Head, Research & CSO, Sanofi

 

8:30 am

CROSS-BORDER COLLABORATION

Ed Hu, Vice Chair & Global CIO, WuXi

 

9:00 am

FIRESIDE CHAT

Lloyd Minor, Dean, Stanford School of Medicine

Marc Tessier-Lavigne, former President, Stanford University

Moderator: Christoph Westphal, General Partner, Longwood Fund

 

9:20 am

ENSURING HEALTH EQUITY AND ACCESS

Steve Hahn, CEO, Harbinger Health; former Commissioner, FDA

Sabrina Johnson, CEO, Daré Bioscience

 

9:50 am

NETWORKING BREAK

 

10:20 am

R&D COLLABORATION

Johan Luthman, EVP, R&D, Lundbeck

Zhen Su, CEO, Marengo Therapeutics

 

10:50 am

ACCELERATING DRUG DEVELOPMENT

Larry Hamann, CEO, Interdict Bio

Carl Hansen, CEO, Abcellera

 

11:20 am

RECRUITING AND RETAINING TALENT

 

11:50 am

FIRESIDE CHAT: FROM PHARMA TO BIOTECH CEO

Hal Barron, CEO, Altos Labs

Mathai Mammen, CEO, FogPharma

 

12:10 pm

NETWORKING LUNCHEON

 

1:00 pm

RARE DISEASE INNOVATION

Shalini Sharp, former CFO, Ultragenyx

 

1:30 pm

GETTING TO REGULATORY APPROVAL

Moderator: Ken Drazan, CEO, ArsenalBio

 

2:00 pm

DEAL-MAKING LANDSCAPE

Matthias Muellenbeck, SVP, Head Global BD & Alliance Management, Merck KGaA

Ioannis Sapountzis, SVP, Corporate BD&L, Boehringer Ingelheim

 

2:30 pm

INNOVATIVE COMMERCIAL MODELS

Teresa Bitetti, President, Global Oncology, Takeda

 

3:00 pm

NETWORKING BREAK

 

3:30 pm

REGULATORY KEYNOTE

Peter Marks, Director, CBER, FDA

 

4:00 pm

THE FUTURE OF GENETIC THERAPIES

 

4:30 pm

STRENGTH IN THE SYNDICATE

Vik Bajaj, Managing Director, Foresite Capital

 

5:00 – 7:00 pm

COCKTAIL RECEPTION

Sunday, January 7, 2024

7:00 am

REGISTRATION & NETWORKING BREAKFAST

 

7:30 am

LONGWOOD FUND INTRODUCTION

 

8:00 am

R&D TRANSFORMATION

Anirvan Ghosh, CEO, Unity Biotechnology

Liz Thompson, EVP, R&D, Horizon Therapeutics

 

8:30 am

INNOVATION IN CLINICAL TRIAL DESIGN

John Glasspool, CEO, Anthos Therapeutics

Paulo Fontoura, SVP, Neuroscience, Immunology, Ophthalmology, Infectious & Rare Diseases Clinical Development, Roche

 

9:00 am

PLATFORM TO PRODUCT PLAY

 

9:30 am

FIRESIDE CHAT

Rochelle Walensky, Director, CDC (2021-2023)

 

9:50 am

NETWORKING BREAK

 

10:20 am

BIG BIOPHARMA R&D

 

10:50 am

MAINTAINING FOCUS ON THE PATIENT

David Loew, CEO, Ipsen

 

11:20 am

EVOLVING PARTNERING STRATEGY

Anat Naschitz, CEO, 9xc

Uli Stilz, VP, Bio Innovation Hub, Novo Nordisk

Matt Tremblay, CEO, Blackbird Labs

 

11:50 am

MANAGING THE RUNWAY

 

12:20 pm

NETWORKING LUNCHEON

 

1:00 pm

POLICY IMPACT ON INNOVATON

 

1:30 pm

ADVANCING RESEARCH INTO THE CLINIC

Stewart Campbell, CEO, Axial Therapeutics

Robert LaCaze, CEO, Mnemo Therapeutics

Sunil Verma, SVP, Global Medical Affairs, Oncology, AstraZeneca

 

2:00 pm

FIRESIDE CHAT: PHARMA R&D TRENDS

 

2:20 pm

NETWORKING BREAK

 

2:40 pm

THE NEXT WAVE OF TARGETED THERAPIES

Janice Chen, CTO, Mammoth Biosciences

Phil Vickers, CEO, Solu Therapeutics

 

2:50 pm

EXTERNAL INNOVATION

Jeb Keiper, CEO, Nimbus Therapeutics


3:20 pm

INVESTMENT OUTLOOK

Accommodations

Supporters

​To learn more about getting involved contact sg@longwoodfund.com

ARE_RGB_Stacked_Tagline_300dpi.jpg
H1.jpg
bottom of page